After five years of use, the Food and Drug Administration FDA accumulated reports of 43 patients undergoing neuraxial blocks who developed spinal hematoma.
Después de cinco años de uso, la Food and Drug Administration FDA ya tenía relatos de 43 pacientes sometidos a bloqueos neuroaxiales que desarrollaron hematoma espinal.
Após cinco anos de uso, a Food and Drug Administration FDA acumulava relatos de 43 pacientes submetidos a bloqueios neuroaxiais que desenvolveram hematoma espinhal.